Advancing Therapy in Basal Insulin-Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline HbA1c, Insulin Dose, and BMI

被引：0
|
作者：
Home, Philip
McCrimmon, Rory J.
Rosenstock, Julio
Bluher, Matthias
Pegelow, Katrin
Melas-Melt, Lydie
Djaballah, Khier
Giorgino, Francesco
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-845-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
845-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Menstrual irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus
    Gaete, Ximena
    Vivanco, Maritza
    Eyzaguirre, Francisca
    Unanue, Nancy
    Lopez, Patricia
    Rhumie, Hana
    Codner, Ethel
    HORMONE RESEARCH, 2009, 72 : 433 - 433
  • [42] Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
    McCrimmon, Rory J.
    Home, Philip
    Cheng, Alice
    Giorgino, Francesco
    Fonseca, Vivian
    Souhami, Elisabeth
    Alvarez, Agustina
    Picard, Pascaline
    Rosenstock, Julio
    DIABETES OBESITY & METABOLISM, 2022, 24 (12): : 2391 - 2399
  • [43] Impact of Automated Insulin Delivery Systems by Baseline HbA1c in Emerging Adults with Type 1 Diabetes
    Waterman, Lauren A.
    Alonso, Guy T.
    Sakamoto, Casey
    Pyle, Laura
    Forlenza, Gregory P.
    Shah, Viral N.
    Cobry, Erin C.
    DIABETES, 2024, 73
  • [44] Effect of Internet Therapeutic Intervention on HbA1c Levels in Patients with Type 2 Diabetes Treated with Insulin
    Tildesley, Hugh D.
    Mazanderani, Adel B.
    Ross, Stuart A.
    DIABETES, 2010, 59 : A134 - A135
  • [45] Immediate feedback of HbA1c levels improves glycemic control in type I and insulin-treated type 2 diabetic patients
    Cagliero, E
    Levina, EV
    Nathan, DM
    DIABETES CARE, 1999, 22 (11) : 1785 - 1789
  • [46] The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting
    Meneghini, Luigi F.
    Mauricio, Didac
    Orsi, Emanuela
    Lalic, Nebojsa M.
    Cali, Anna M. G.
    Westerbacka, Jukka
    Stella, Peter
    Candelas, Christophe
    Pilorget, Valerie
    Perfetti, Riccardo
    Khunti, Kamlesh
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1429 - 1436
  • [47] Reduced risk of hypoglycaemia and lower HbA1c with degludec compared to glargine U300 in insulin-treated patients with type 2 diabetes
    Philis-Tsimikas, A.
    Klonoff, D. C.
    Khunti, K.
    Bajaj, H. S.
    Leiter, L. A.
    Tutkunkardas, D.
    Troelsen, L. Norgard
    Bak, B. A.
    Heller, S. R.
    Pieber, T. R.
    DIABETOLOGIA, 2019, 62 : S47 - S47
  • [48] Superior HbA1c reduction with Basal Insulin peglispro (BIL) vs insulin glargine in patients with type 2 diabetic patients previously treated with basal insulin: IMAGINE 5
    Trescoli Serrano, C.
    Buse, J. B.
    Rodbard, H. W.
    Luo, J.
    Ivanyi, T.
    Bue-Valleskey, J.
    Hartman, M. L.
    Carey, M. A.
    Chang, A. M.
    DIABETOLOGIA, 2015, 58 : S470 - S470
  • [49] Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies
    Riddle, M. C.
    Vlajnic, A.
    Zhou, R.
    Rosenstock, J.
    DIABETES OBESITY & METABOLISM, 2013, 15 (09): : 819 - 825
  • [50] Near-normoglycaemia and insulin regression induced by tirzepatide in basal insulin-treated type 2 diabetes
    Patel, H.
    Tofe, S.
    Wysham, C.
    Thieu, V. T.
    Kiljanski, J.
    Lee, C.
    Wang, H.
    Rosenstock, J.
    DIABETOLOGIA, 2024, 67 : S361 - S361
12345